Fig. 2From: Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol useProportion of participants with HIV and opioid use disorder who initiated clinic-based buprenorphine in each opioid use disorder treatment stage in the Johns Hopkins HIV Clinical Cohort restricted to 4-year follow-up, with retention defined as ≥ 180 days of treatment without a > 7-day gapBack to article page